Results 221 to 230 of about 11,453 (268)
Some of the next articles are maybe not open access.
Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban
Vascular Pharmacology, 2016Glycoprotein (GP) IIb/IIIa inhibitors block platelet aggregation, reducing thrombotic events in acute coronary syndrome. They are most often utilized in patients who likely have an intracoronary thrombus. Tirofiban, eptifibatide, and abciximab are the three GP IIb/IIIa inhibitors approved for use in the United States.
Marintha Short +2 more
exaly +4 more sources
Safety evaluation of tirofiban
Expert Opinion on Drug Safety, 2010Heightened platelet activity is pivotal in the thrombosis underlying acute coronary syndrome (ACS). The glycoprotein IIb/IIIa inhibitor tirofiban is a powerful platelet inhibitor with demonstrated efficacy and safety across the spectrum of ACS. Despite tirofiban's impact on the platelet compared with placebo, only an excess in minor and importantly not
Marco Valgimigli, Matteo Tebaldi
openaire +3 more sources
Risedronate Sodium and Tirofiban Hydrochloride [PDF]
Hospital Pharmacy, 1999 Each month, subscribers to The Formulary® receive print and electronic versions of at least six monographs reviewing new drug entities or related drugs within a category. Some reviews take a second look at currently available drugs, whereas other preliminarily evaluate agents about to be released—just in time for use with your Pharmacy and ...
Danial E. Baker, Terri Levien
openaire +1 more source
Tirofiban for myocardial infarction
Expert Opinion on Pharmacotherapy, 2010Inhibition of platelet aggregation plays a key role in treatment of coronary artery disease.Studies on the effects of tirofiban in patients with either ST elevation or non-ST elevation myocardial infarction are reviewed.Tirofiban is a small-molecule glycoprotein IIb/IIIa receptor inhibitor. If discontinued, the action of tirofiban is faster reversed as
Harry Suryapranata +3 more
openaire +2 more sources
Tirofiban for the treatment of ischaemic stroke
Expert Opinion on Pharmacotherapy, 2005Tirofiban is one of three glycoprotein IIb/IIIa receptor antagonists approved by the US FDA, beside abciximab and eptifibatide. The approval of tirofiban covers conservative treatment of myocardial infarction and unstable angina, as well as percutaneous coronary intervention, for which treatment with tirofiban is recommended in moderate-to-high-risk ...
Michael Daffertshofer +2 more
openaire +3 more sources